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SUMMARY
OBJECTIVE—To evaluate the cost-effectiveness of the Three I’s for HW/TB (human 
immunodeficiency virus/tuberculosis): antiretroviral therapy (ART), intensified TB case finding 
(ICF), isoniazid preventive treatment (IPT), and TB infection control (IC).
METHODS—Using a 3-year decision-analytic model, we estimated the cost-effectiveness of a 
base scenario (55% ART coverage at CD4 count ≤350 cells/mm3) and 19 strategies that included 
one or more of the following: 1) 90% ART coverage, 2) IC and 3) ICF using four-symptom 
screening and 6- or 36-month IPT. The TB diagnostic algorithm included 1) sputum smear 
microscopy with chest X-ray, and 2) Xpert® MTB/RIF.
RESULTS—In resource-constrained settings with a high burden of HIV and TB, the most cost-
effective strategies under both diagnostic algorithms included 1) 55% ART coverage and IC, 2) 
55% ART coverage, IC and 36-month IPT, and 3) expanded ART at 90% coverage with IC and 36-
month IPT. The latter averted more TB cases than other scenarios with increased ART coverage, 
IC, 6-month IPT and/or IPT for tuberculin skin test positive individuals. The cost-effectiveness 
results did not change significantly under the sensitivity analyses.
CONCLUSION—Expanded ART to 90% coverage, IC and a 36-month IPT strategy averted most 
TB cases and is among the cost-effective strategies.
RESUME
Nous évaluons le rapport coût-efficacité de l’approche des « 3 I » dans la lutte contre le virus de 
l’immunodéficience humaine (VIH) et la TB : traitement antirétroviral (ART) et intensification de 
la recherche de cas de TB (ICF), traitement préventif par isoniazide (IPT) et lutte contre l’infection 
tuberculeuse (IC).
Nous avons estimé, grâce à un modèle de décision analytique de 3 ans, le rapport coût-efficacité 
d’un scénario de base (55% de couverture du traitement ART quand la numération des CD4 est 
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≤350 cellules/mm3) et 19 stratégies qui incluaient une ou plusieurs des stratégies suivantes : 1) 
90% de couverture par ART, 2) IC et 3) ICF grâce à un dépistage basé sur quatre symptômes et un 
IPT pendant 6 ou 36 mois. L’algorithme de diagnostic de la TB incluait 1) microscopie des frottis 
de crachats et radio pulmonaire et 2) Xpert® MTB/RIF.
Dans les contextes ressources limitées confrontés à un lourd fardeau de VIH et de TB, les 
stratégies les plus rentables en termes d’algorithmes de diagnostic incluaient 1) 55% de couverture 
par ART et IC; 2) 55 % de couverture par ART, IC et 36 mois d’IPT; et 3) expansion de l’ART à 
une couverture de 90% avec IC et IPT de 36 mois. Cette dernière stratégie a évité davantage de cas 
de TB que les autres scénarios avec augmentation de la couverture par ART, IC, 6 mois d’IPT 
et/ou IPT pour les cas positifs au test cutané tuberculinique. Les résultats en termes de coût-
efficacité n’ont pas changé significativement avec les analyses de sensibilité.
La stratégie d’expansion de la couverture par ART à 90%, IC et 36 mois d’IPT a évité le plus de 
cas de TB et elle est parmi les stratégies les plus rentables.
RESUMEN
Se llevó a cabo una evaluación de la rentabilidad de las intervenciones de prevención de la 
tuberculosis (TB), el tratamiento antirretrovírico (ART) y la estrategia de las ‘Tres íes’ (que 
comporta la intensificación de la búsqueda de casos [ICF] de coinfección por el virus de la 
inmunodeficiencia humana [VIH] y TB, el tratamiento preventive con isoniazida [IPT] y el control 
de la infección [IC] tuberculosa).
Se construyó unmodelo analítico decisional destinado a evaluar en una población positiva frente al 
VIH durante un período de 3 años, la rentabilidad de la prevención de la TB en un contexto 
hipotético de base (cobertura del 55% con el ART en pacientes con recuentos de linfocitos CD4 
≤350 células/µl) y en 19 estrategias comparativas que comportaban una o varias de las siguientes 
condiciones: 1) una cobertura del 90% con el ART, 2) medidas de IC tuberculosa y 3) la ICF 
mediante un sistema de detección por cuatro síntomas y el IPT durante 6 meses o 36 meses en los 
casos negatives. Se compararon todas las estrategias al usar dos algoritmos diagnósticos 
diferentes: 1) la baciloscopia del esputo con radiografía de tórax y 2) la prueba Xpert® MTB/RIF.
En los entornos con recursos limitados y una alta carga de morbilidad por TB e infección por el 
VIH, las estrategias más rentables con ambos algoritmos diagnósticos fueron: 1) una cobertura del 
55% con el ART y las medidas de IC tuberculosa; 2) una cobertura del 55% con el ART y 36 
meses de IPT; y 3) la ampliación de la cobertura con el ART al 90%, con medidas de IC 
tuberculosa y 36 meses de IPT. Esta última estrategia evitó más casos de TB que otras dos 
hipótesis con ampliación de la cobertura a 90%, IC y 6 meses de IPT o con tratamiento preventive 
en los casos de reacción tuberculínica positiva. Los resultados de rentabilidad no se modificaron 
de manera significativa en los análisis de sensibilidad.
La estrategia que comporta la ampliación de la cobertura con el ART a 90%, las medidas de IC 
tuberculosa y el IPT durante 36 meses evitó el mayor número de casos de TB y es rentable.
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The human immunodeficiency virus (HIV) infection and tuberculosis (TB) epidemics are 
major threats to global public health. About one third of the 35.3 million people living with 
HIV are latently infected with Mycobacterium tuberculosis, and are more likely to develop 
active TB disease than people who are not infected with HIV
1,2 The World Health 
Organization (WHO) recommends the Three I’s for HIV/TB and early initiation of 
antiretroviral therapy (ART) to reduce the burden of TB in HIV-positive people.
3
 They 
include 1) intensified TB case finding (ICF), 2) TB prevention with isoniazid preventive 
treatment (IPT) and early ART, and 3) TB infection control (IC) in health care facilities and 
congregate settings.
A recent systematic review confirmed that ART reduces the risk of developing TB by 65% 
across all CD4 count strata.
4
 The expansion of ART coverage also reduces TB incidence at 
the community and population levels in settings with a large burden of HIV-associated 
TB.
5,6 The 2010 WHO ART guidelines recommend ART initiation at CD4 count ≤350 
cells/mm3 for all asymptomatic people living with HIV, and irrespective of CD4 cell count 
for those with active TB.
7
 More recently, the WHO recognised the benefits of earlier 
treatment and recommended ART at CD4 count ≤500 cells/mm3 and irrespective of CD4 
count for serodiscordant couples, pregnant women, children aged <5 years and persons with 
TB or hepatitis B.
8
 The 2011 WHO ICF/IPT guidelines recommend four-symptom 
screening (current cough, fever, weight loss or night sweats) to identify HIV-infected 
persons eligible for either IPT or further diagnostic work-up for TB and other conditions.
9 
The tuberculin skin test (TST) is not a requirement for the administration of IPT, but may be 
used where feasible.
9
 The 2009 WHO policy on IC proposes managerial, administrative and 
environmental controls and personal protection measures in health facilities to reduce the 
risk of nosocomial TB transmission.
10
Most countries currently recommend and implement different TB prevention strategies to 
reduce morbidity and mortality among people living with HIV This study evaluates the cost-
effectiveness of different TB prevention strategies in a setting with a generalised HIV 
epidemic and high TB burden among people living with HIV to determine the optimal mix 
of interventions that will maximise health benefits with the given resources.
METHODS
We developed a decision-analytic model (Appendix Figure A.1)* to estimate the cost-
effectiveness of TB prevention strategies in a hypothetical cohort of 10 000 HIV-positive 
people with a prevalence of active TB of 5%. TB prevention interventions were provided at 
time zero, and the cohort was followed up for a period of 3 years. Ethical approval was not 
required for the study. The model for Year 1 was constructed using TreeAge 2012 (TreeAge 
Software, Inc, Williamstown, MA, USA). TB cases among people living with HIV and costs 
in subsequent years were calculated using Microsoft Excel 2011 (Microsoft, Redmond, WA, 
USA).
*The Appendix is available in the online version of this article, at http://www.ingentaconnect.com/content/iuatld/ijtld/
2014/00000018/00000010/art00006.
Gupta et al. Page 3













The base scenario was defined as one with ART coverage at the 2011 global ART coverage 
rate of 55% (at CD4 count ≤350 cells/mm3).
11
 The TB symptom considered for screening 
was current cough. The 19 comparative strategies included one or more of the following TB 
prevention interventions: 1) ART coverage increased to 90% at CD4 count ≤350 cells/mm3; 
2) IC measures in health care facilities, which included administrative measures such as 
triage, personal protective measures such as respirators for nurses and surgical masks for 
patients with cough and natural ventilation through construction and maintenance of fans 
and windows; and 3) ICF using a four-symptom screening algorithm and 6-month or 36-
month IPT (life-long IPT) for those screening negative (Table 1). The costs and number of 
TB cases were calculated for all strategies under two separate TB diagnostic algorithms: 1) 
sputum smear microscopy with chest X-ray (CXR); and 2) Xpert® MTB/RIF assay for 
diagnosis of Mycobacterium tuberculosis and resistance to rifampicin (Cepheid, Sunnyvale, 
CA, USA).
Model parameters and assumptions
The parameter values for TB prevalence, TB incidence, sensitivity and specificity of TB 
screening and diagnostic tests and the efficacy of the TB prevention interventions were 
derived from the published literature (Table 2).
11–24 Outcomes and costs related to drug-
resistant TB were not considered in the analysis.
We chose a 3-year analytic horizon to be able to compare the preventive effect of long-term 
IPT use (i.e., 36 months) against the use of short-term IPT (i.e., 6 months). We assumed that 
the 6 months of IPT would be effective for a period of 1 year. We assumed that the 
effectiveness of the IC package was similar to that of a study investigating the effects of IC 
measures in the epidemic trajectory of a setting with high TB-HIV co-infection.
12
Costs
The analysis took a health system perspective and considered health care utilisation costs 
from South Africa (Table 3).
9,25–30 Development and maintenance costs of diagnostic 
capacity, productivity loss and out-of-pocket costs incurred by individuals to seek care were 
not included. Costs for TB diagnostic tests and drugs were derived from published studies; 
in-patient and out-patient costs came from WHO-CHOICE (CHOosing Interventions that 
are Cost Effective).
28
 Cost data for IC interventions were taken from a primary health care 
facility in South Africa, and building cost indices from the Bureau of Economic Research, 
Stellenbosch University, Cape Town, South Africa.
Using the South African consumer price index for medical goods and services from 2006 to 
2012 (Statistics South Africa, South Africa Consumer Price Index, Pretoria, South Africa, 
http://www.statssa.gov.za), all the costs were converted into 2010 USD and adjusted for 
inflation for 2011 and 2012.
Cost-effectiveness analysis
The primary outcome of the analysis was cases of TB averted, calculated as the difference 
between the number of TB cases under two different strategies. The incremental cost-
effectiveness ratio (ICER) was calculated as the ratio of the difference between total costs 
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under alternative TB prevention strategies to the TB cases averted. This ratio was expressed 
in terms of US dollars spent in health care costs per TB case averted. Strategies that 
prevented fewer TB cases and at greater cost compared to other strategies (i.e., strongly 
dominated), and strategies with higher ICER than the next most effective alternative (i.e., 
weakly dominated) were excluded from the incremental analysis.
Sensitivity analysis
For strategies under the two TB diagnostic algorithms, univariate sensitivity analyses were 
performed using TreeAge for Year 1 using calculations of net monetary benefit. For different 
willingness-to-pay (WTP) thresholds, we generated tornado diagrams for all parameters 
except for those that were common across all policy alternatives. The ranges for relative risk 
(RR) of TB from different interventions, and the sensitivity and specificity of TB screening 
and diagnostic tests came from the published literature. Cost inputs were varied by 50–200% 
of their base values. We considered two WTP thresholds: 1) US$1000 (approximate cost of 
diagnosis and treatment of active TB) and 2) US$35 000 (equivalent to highest ICER value 
generated when only TB prevention benefits of ART are taken into account). We further 
conducted threshold analysis for parameters with the greatest influence on outcomes to 
determine the value at which other alternatives become more effective. We also conducted 
Monte Carlo simulation probabilistic sensitivity analysis (PSA) and compared the two most 
comprehensive strategies: ‘ART IC ICF IPT 36′ and ‘ARTexp IC ICF IPT 36′ (Appendix 
Figure A.2).
RESULTS
TB diagnostic algorithm: sputum smear and chest radiography
Considering sputum smear and CXR as the diagnostic tool for TB, the ‘base scenario’ cost 
US$3.4M and resulted in 1289 TB cases per 10 000 HIV-positive people. The most cost-
effective strategies included 1) 55% ART coverage and IC (‘ART IC’), 2) 55% ART 
coverage, IC and 36-month IPT (‘ART IC ICF IPT 36’) and 3) expanded ART coverage with 
IC and 36-month IPT (‘ARTexp IC ICF IPT 36’) (Appendix Figure A.3). Adding IC averted 
99 TB cases at an additional cost of US$34 000 (ICER = US$342). Compared to the ‘ART 
IC ICF IPT 36′ scenario, the ‘ARTexp IC ICF IPT 36′ scenario averted 47 TB cases and cost 
an additional US$1.5M. This resulted in an ICER of US$31 463 (Appendix Table A.1). The 
ICER would likely be far less if it took into account the other benefits of ART beyond TB 
prevention.
Strategies with ICF using four-symptom screening and IPT for 6 or 36 months were weakly 
dominated when compared with corresponding strategies with IC, which prevented 
additional TB cases at a small net cost. Increasing the duration of IPT from 6 to 36 months 
prevented a substantial number of TB cases, such that the strategies with 6-month IPT were 
weakly dominated. Although TB incidence was not significantly lower in TST-negatives 
receiving IPT, strategies with IPT for all people living with HIV dominated the strategies 
that provided IPT to TST-positive people living with HIV.
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TB diagnostic algorithm: Xpert MTB/RIF
The results remained consistent with Xpert as the TB diagnostic tool. The base scenario cost 
US$3.3M, and resulted in 1308 TB cases per 10 000 HIV-positive people (Appendix Figure 
A.4). The ‘ART IC’ scenario averted 101 TB cases at an additional cost of US$33 900 
(ICER = US$336). The ‘ARTexp IC ICF IPT 36’ scenario prevented 51 additional TB cases 
over the ‘ART IC ICF IPT 36’ scenario at an incremental cost of US$1.5M, resulting in an 
ICER of US$28 936 (Appendix Table A.1). This ICER would likely be markedly lower if 
we consider the benefits of ART beyond TB prevention.
Sensitivity analysis
For both the diagnostic algorithms, six parameters accounted for variations in cost-
effectiveness results at a WTP threshold of US$1000: ART coverage, sensitivity and 
specificity of TB screening with cough, the RR of TB from ART and from IC, and cost of 
IC. At the higher WTP threshold of US$35 000; the RR of TB from 1) continuous IPT vs. 6-
month IPT, 2) 6-month IPT for TST-negative and 3) IC, and cost of 36-month IPT were 
responsible for maximum variation in the ICERs (Appendix Figures A.5 and A.6). 
Threshold analyses showed that for an RR of TB from IC of >0.985 (at WTP threshold of 
US$1000) and 0.994 (at WTP threshold of US$35 000), the alternatives without IC would be 
cost-effective compared to the corresponding scenarios with IC. At a high WTP for a TB 
case averted (US$35 000), PSA revealed that the ‘ARTexp IC ICF IPT 36′ strategy would be 
preferred to the ‘ART IC ICF IPT 36’ scenario 13% of the time (Appendix Figure A.2). 
However, the probability of choosing the expanded ART strategy would likely be much 
higher if we include benefits beyond preventing TB.
DISCUSSION
Effective anti-tuberculosis treatment remains a key strategy to reduce TB incidence, but this 
approach is unlikely to contain the rise in incidence resulting from HIV. In high HIV burden 
settings, the health systems need to be strengthened to provide the Three I’s for HIV/TB, 
including early ART for people living with HIV. We calculated the cost-effectiveness of 
these WHO-recommended TB prevention strategies using a decision-analytic model.
This is the first study to estimate the costs and benefits of the Three I’s for HIV/TB 
including ART together under different WHO-recommended TB diagnostic algorithms. Our 
findings suggest that in resource-constrained settings with a high burden of HIV and TB, a 
complete TB prevention package with 90% ART coverage at CD4 ≤350 cells/mm3, IC 
interventions and IPT for 36 months averted more TB cases than other scenarios with 
increased ART coverage, IC, 6-month IPT and/or IPT for TST-positives. This scenario, 
along with the ‘ART IC and ‘ART IC ICF IPT 36’ scenarios, was among the most cost-
effective strategies.
The health care utilisation costs from South Africa may be higher than in other countries. 
Our results were therefore probably an overestimation of the true cost of TB diagnosis and 
treatment in many TB-HIV-endemic countries. While the portability of health care costs may 
restrict the interpretation of the costs and cost-effectiveness ratios to countries with higher 
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costs, it does not change our conclusions about the effectiveness of the interventions 
evaluated in this study.
The figures for scenarios involving ART at 90% coverage need to be interpreted with 
caution, as we did not consider the impact of expanded access to ART on other HIV-related 
illnesses. Studies from similar settings have shown that increasing the provision of ART is 
highly cost-effective or cost saving for reducing the HIV- and TB-related burden (e.g., 
ICERs of US$530–590 per life-year saved in India and South Africa).
31,32 Thus, the 
scenario with 90% ART coverage, IC and 36-month IPT will likely be more cost-effective 
when prevention benefits of ART beyond TB are considered. We also did not explore the 
potential impact of using the WHO 2013 guidelines or the initiation of ART regardless of 
CD4 count on TB incidence. We assumed the ART eligibility criteria to be CD4 count ≤350 
cells/mm3, as recommended by the 2013 ART guidelines from South Africa. As ART 
prevents TB across all CD4 cell counts,
4
 it is likely that the scenarios with ART at CD4 
count ≤500 cell/mm3 or regardless of CD4 count along with the Three I’s for HIV/TB will 
be cost-effective. In addition, we did not consider the effects of expanded ART coverage on 
the prevention of HIV transmission to sexual partners and children, which could have a 
considerable impact on the TB burden.
33
The effect of IC measures on nosocomial transmission of TB and the costs of these 
interventions are not well documented, and the assumption that a TB prevention package 
with respirators, surgical masks and natural ventilation will cost US$3.4 per person is an 
estimate. We kept our model simple by assuming that TB prevention interventions are 
independent of one another. We did not model long-term TB or HIV transmission dynamics, 
and estimated the costs and benefits of one-time TB screening over a period of 3 years. We 
did not consider the potential impact of Xpert on TB incidence by reducing the time between 
detection and initiation of appropriate treatment for TB.
Our study highlights the importance of the Three I’s for HIV/TB, including expanded ART 
coverage to address TB, in communities with high HIV and TB prevalence. The availability 
of these interventions has significantly improved in sub-Saharan Africa. In 2012, according 
to the WHO 2010 guidelines, ART coverage was >80% in six countries.
2
 An estimated 2.3 
million people were screened for TB, a two-fold increase from 860 000 in 2009. IPT was 
initiated among 470 000 people newly registered in HIV care in 2012, compared to <50 000 
people in 2009.
1
However, despite this remarkable progress, the vast majority of people who could benefit 
from these interventions do not have access. Likewise, IC for TB is often not a priority for 
many HIV and TB programmes. Expanding access to HIV treatment remains a priority, as 
coverage of the 28.6 million people eligible for ART (per the WHO 2013 guidelines) is less 
than 40%. Our study highlighted the potential cost-effectiveness of the Three Is for HIV/TB, 
including early ART, in preventing TB from a health sector perspective. However, it is likely 
to be even more cost-effective to prevent both TB and HIV with these interventions if we 
take the significant societal and individual costs of these diseases into consideration. In 
addition to the health benefits for the individual and the community, national TB and HIV/
AIDS (acquired immune-deficiency syndrome) programmes may benefit from considering 
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the economic implications of TB prevention as they develop an integrated approach to 
ensuring people living with HIV have access to high-quality HIV and TB prevention, care 
and treatment services.
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Costs, outcomes and ICERs (in USD spent in health care costs/TB case averted)










Base* 1289 3 434 704
ART IC* 1190 3 468 604 99 33 900 342
ARTexp 1180 4 941 979 10 1 473 375 147 338
ART ICF IPT 6* 1168 4 502 542 12 −439437 (36 620)
ARTexp IC 1094 4 975 879 74 473 337 6 396
ART IC ICF IPT 
6*
1084 4 485 802 10 −490 077 (49 008)
ARTexp ICF IPT 
6
1076 5 954 018 8 1 468 216 183 527
ARTexp IC ICF 
IPT 6
1002 5 943 379 74 −10 639 (144)
ART ICF TST 
IPT 36*
988 4 739 030 14 −1 204 349 (86 025)
ART ICF IPT 6 
TST IPT 36
974 4 874 713 14 135 683 9 692
ART IC ICF TST 
IPT 36*
926 4 743 516 48 −131 197 (2 733)
ARTexp ICF TST 
IPT 36
919 6 212 020 7 1 468 504 209 786
ART IC ICF IPT 
6 TST IPT 36*
915 4 872 908 4 −1339 112 (334 778)
ARTexp ICF IPT 
6 TST IPT 36
908 6 341 615 7 1 468 707 209815
ART ICF IPT 
36*
888 5 097 662 20 −1 243 953 (62 198)
ARTexp IC ICF 
TST IPT 36
865 6 220 368 23 1 122 706 48813
ARTexp IC ICF 
IPT 6 TST IPT 
36
856 6 344 626 9 124 258 13 806
ART IC ICF IPT 
36*
838 5 101 438 18 −1243 188 (69 066)
ARTexp ICF IPT 
36
833 6 571 933 m 1 470 495 294099
ARTexp IC ICF 
IPT 36*
791 6 580182 42 8 249 196
Ai) After removing the dominated strategies from incremental analysis:
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Base* 1289 3 434 704
ART IC* 1190 3 468 604 99 33 900 342
ART ICF IPT 6 1168 4 502 542 22 1 033 938 46 997
ART IC ICF IPT 
6*
1084 4485 802 84 −16 740 (199)
ART ICF TST 
IPT 36
988 4 739 030 96 253 228 2 638
ART IC ICF TST 
IPT 36*
926 4 743 516 62 4 486 72
ART IC ICF IPT 
6 TST IPT 36
915 4 872 908 11 129 392 11 763
ART ICF IPT 36 888 5 097 662 27 224754 8 324
ART IC ICF IPT 
36*
838 5 101 438 50 3 776 76
ARTexp IC ICF 
IPT 36*











Base* 1289 3 434 704
ART IC* 1190 3 468 604 99 33 900 342
ART IC ICF IPT 
6
1084 4485 802 106 1 017198 9 596
ART IC ICF TST 
IPT 36*
926 4 743 516 158 257714 1 631
ART IC ICF IPT 
36*
838 5 101 438 88 357 922 4 067
ARTexp IC ICF 
IPT 36*











Base* 1289 3 434 704
ART IC* 1190 3 468 604 99 33 900 342
ART IC ICF TST 
IPT 36
926 4 743 516 264 1 274912 4 829
ART IC ICF IPT 
36*
838 5 101 438 88 357 922 4 067
ARTexp IC ICF 
IPT 36*
791 6 580182 47 1 478 744 31463
B) Incremental cost-effectiveness ratios for the cost-effective strategies
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Base* 1289 3 434 704
ART IC* 1190 3 468 604 99 33 900 342
ART IC ICF IPT 
36*
838 5 101 438 352 1 632 834 4639
ARTexp IC ICF 
IPT 36*
791 6 580182 47 1 478 744 31463










Base* 1308 3 315 687
ART ICF IPT 6 1221 4 207 407 87 891 720 10250
ART IC* 1207 3 349 587 14 −857 820 (61 273)
ARTexp 1197 4 822 962 10 1 473 375 147 338
ART IC ICF IPT 
6*
1129 4185 320 68 −637 642 (9 377)
ARTexp ICF IPT 
6
1120 5 652 851 9 1 467 531 163 059
ARTexp IC* 1109 4 856 862 11 −795 989 (72 363)
ARTexp IC ICF 
IPT 6
1042 5 639 057 67 782 195 11 675
ART ICF TST 
IPT 36*
1018 4490 753 24 −1 148 304 (47 846)
ART ICF IPT 6 
TST IPT 36
1004 4 626 362 14 135 609 9 686
ART IC ICF TST 
IPT 36*
954 4493 283 50 −133 079 (2 662)
ARTexp ICF TST 
IPT 36
944 5 960 442 10 1 467 1 59 146716
ART IC ICF IPT 
6 TST IPT 36*
942 4 622 591 2 —1 337 851 (668 926)
ARTexp ICF IPT 
6 TST IPT 36
935 6 091 225 7 1 468 634 209 805
ART ICF IPT 
36*
919 4 849 293 16 —1 241 932 (77621)
ARTexp IC ICF 
TST IPT 36
889 5 967 624 30 1 118331 37278
ARTexp IC ICF 
IPT 6 TST IPT 
36
880 6 091 822 9 124198 13 800
ART IC ICF IPT 
36*
866 4851 163 14 —1 240 659 (88 619)
ARTexp ICF IPT 
36
859 6319731 7 1 468 568 209795
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ARTexp IC ICF 
IPT 36*
815 6 326 899 44 7 168 163










Base* 1308 3 315 687
ART IC* 1207 3 349 587 101 33 900 336
ART IC ICF IPT 
6*
1129 4185 320 78 835 733 10715
ARTexp IC 1109 4 856 862 20 671 542 33 577
ART ICF TST 
IPT 36*
1018 4490 753 91 −366109 (4 023)
ART IC ICF TST 
IPT 36*
954 4493 283 64 2 530 40
ART IC ICF IPT 
6 TST IPT 36
942 4 622 591 12 129308 10 776
ART ICF IPT 36 919 4 849 293 23 226702 9 857
ART IC ICF IPT 
36*
866 4851 163 53 1 870 35
ARTexp IC ICF 
IPT 36*
815 6 326 899 51 1 475 736 28 936










Base* 1308 3 315 687
ART IC* 1207 3 349 587 101 33 900 336
ART IC ICF IPT 
6
1129 4185 320 78 835 733 10715
ART ICF TST 
IPT 36
1018 4490 753 111 305 433 2 752
ART IC ICF TST 
IPT 36*
954 4493 283 64 2 530 40
ART IC ICF IPT 
36*
866 4851 163 88 357 880 4 067
ARTexp IC ICF 
IPT 36*











Base* 1308 3 315 687
ART IC* 1207 3 349 587 101 33 900 336
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ART IC ICF TST 
IPT 36
954 4493 283 253 1 143 696 4 521
ART IC ICF IPT 
36*
866 4851 163 88 357 880 4 067
ARTexp IC ICF 
IPT 36*
815 6 326 899 51 1 475 736 28936
D) Incremental cost-effectiveness ratios for the cost-effective strategies





Base* 1308 3 315 687
ART IC* 1207 3 349 587 101 33 900 336
ART IC ICF IPT 
36*
866 4851 163 341 1 501 576 4 403
ARTexp IC ICF 
IPT 36*
815 6 326 899 51 1 475 736 28936
*
Non-dominated strategies (defined in the main paper)
ICER = incremental cost-effectiveness ratio; USD = US dollars; TB = tuberculosis; ART =antiretroviral therapy; IC = 
infection control; ARTexp = expanded ART (90% coverage); IPT = isoniazid preventive therapy; ICF = intensified TB case 
finding; TST = tuberculin skin test.
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Decision tree. TB was diagnosed using sputum smear and chest radiography or Xpert® 
MTB/RIF. * Standard TB screening is using cough; enhanced TB screening refers to the 
WHO-recommended four-symptom screening algorithm. PLHIV = people living with HIV; 
TB = tuberculosis; IC = infection control;+= positive;-= negative; ART=antiretroviral 
therapy; TST = tuberculin skin test; IPT = isoniazid preventive therapy; WHO = World 
Health Organization.
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Probabilistic sensitivity analysis. A) Cost-effectiveness acceptability curve; B) strategy 
selection (willingness-to-pay/TB case averted = USD35 000). We ran 10 000 iterations of 
the model for Year 1 using Monte Carlo simulation probabilistic sensitivity analysis and 
compared the two most comprehensive strategies that were also among the cost-effective 
strategies (ART IC ICF IPT 36 and ARTexp IC ICF IPT 36, Xpert TB diagnostic algorithm). 
We set distribution for only those variables found to be influential in the oneway sensitivity 
analysis under the two willingness-to-pay thresholds of USD1000 and 35 000 (ART 
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coverage, relative risk of TB from ART and from IC, cost of IC interventions and cost of 
IPT). The result of the probabilistic sensitivity analysis using the willingness-to-pay 
threshold of USD35 000 indicated that we will choose the ART IC ICF IPT 36 strategy 32% 
of the time and we will be indifferent between both the strategies 55% of the time. We will 
choose the ARTexp IC ICF IPT 36 strategy 13% of the time. Note that strategy selection is 
based on costs and outcomes of the scenarios in Year 1. The probability of choosing ARTexp 
IC ICF IPT 36 strategy is likely to be higher over a 3-year period. Furthermore, the 
probability of choosing the expanded ART strategy would likely be much higher if we 
include benefits of ART beyond the prevention of TB. ART=antiretroviral therapy; IC = 
infection control; ICF = intensified case finding; PT = isoniazid preventive therapy; ARTexp 
= expanded ART (90% coverage); USD = US dollars.
Figure A.3. 
Expected costs and TB cases (TB diagnostic algorithm: sputum smear and chest 
radiography). Note: The description of the strategies (A to T) is given in Table 1. Base (A), 
ART IC (B), ART IC ICF IPT 36 (H) and ARTexp IC ICF IPT 36 (R) scenarios were most 
cost-effective. The total TB cases and total costs under each strategy are available in the 
Online Appendix. USD = US dollars; TB = tuberculosis; ART =antiretroviral therapy; IC = 
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infection control; ICF = intensified case finding; IPT = isoniazid preventive therapy; 
ARTexp = expanded ART (90% coverage).
Figure A.4. 
Expected costs and TB cases (TB diagnostic algorithm: Xpert® MTB/RIF assay). Note: The 
description of the strategies (A to T) is given in Table 1. Base (A), ART IC (B), ART IC ICF 
IPT 36 (H) and ARTexp IC ICF IPT 36 (R) scenarios were most cost-effective. The total TB 
cases and total costs under each strategy are available in the Online Appendix. USD = US 
dollars; TB = tuberculosis; ART=antiretroviral therapy; IC = infection control; ICF = 
intensified case finding; IPT= isoniazid preventive therapy; ARTexp = expanded ART (90% 
coverage).
Gupta et al. Page 19














Tornado diagram of univariate analyses for strategies with sputum smear and chest 
radiography for TB diagnosis. A) Willingness-to-pay threshold of USD1000. Note: the 
diagram shows the degree to which uncertainty in current ART coverage, specificity and 
sensitivity of TB screening with cough, the RR of TB from IC and ART and cost of IC 
interventions accounted for 100% variation in cost-effectiveness results. Variations in other 
parameters (cost of TST, IPT and anti-tuberculosis treatment, sensitivity and specificity of 
four-symptom screening, the RR of TB from 6-month or 36-month IPT, proportion of people 
testing TST-positive of those with active TB and without active TB, and expanded ART 
coverage) had no effect on the results. B) Willingness-to-pay threshold of USD35 000. Note: 
this diagram shows the degree to which uncertainty in RR of TB from continuous IPT vs. 6-
month IPT, 6-month IPT for TST-negatives and IC and cost of 36-month IPT accounted for 
nearly 100% variation in cost-effectiveness results. Variations in other parameters (cost of 
TST and anti-tuberculosis treatment, sensitivity and specificity of TB screening using cough 
or four-symptom screening, proportion of people testing TST-positive of those with active 
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TB and without active TB, and expanded ART coverage) had no effect on the results. ART = 
antiretroviral therapy; RR = relative risk; TB = tuberculosis; IC = infection control; IPT = 
isoniazid preventive therapy; TST = tuberculin skin test; USD = US dollars.
Figure A.6. 
Tornado diagram of univariate analyses for strategies with Xpert® MTB/RIF for TB 
diagnosis. A) Willingness-to-pay threshold of USD1000. Note: the diagram shows the 
degree to which uncertainty in current ART coverage, specificity and sensitivity of TB 
screening with cough, RR of TB from IC and ART, and cost of IC interventions accounted 
for 100% variation in cost-effectiveness results. Variations in other parameters (cost of TST, 
IPT and anti-tuberculosis treatment; sensitivity and specificity of four-symptom screening; 
RR of TB from 6-month or 36-month IPT; proportion of people testing TST-positive of 
those with active TB and without active TB; and expanded ART coverage) had no effect on 
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the results. B) Willingness-to-pay threshold of USD35 000. Note: this diagram shows the 
degree to which uncertainty in RR of TB from continuous IPT vs. 6-month IPT, 6-month 
IPT for TST-negative, and IC and cost of 36-months IPT accounted for nearly 100% 
variation in cost-effectiveness results. Variations in other parameters (cost of TST and anti-
tuberculosis treatment; sensitivity and specificity of TB screening using cough; sensitivity of 
four-symptom screening; proportion of people testing TST-positive of those with active TB 
and without active TB; and expanded ART coverage) had no effect on the results. ART 
=antiretroviral therapy; RR = relative risk; TB = tuberculosis; IC = infection control; IPT = 
isoniazid preventive therapy; TST = tuberculin skin test; USD = US dollars.
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Table 2
Model parameter inputs and their range
Variables Base value Range Source (author, year, reference)
TB prevalence among HIV-positive people 0.05 0.004–0.26 Getahun, 2011
13
Proportion of PLHIV eligible for ART at CD4
count ≤350 cells/mm3, % 45 43–49 UNAIDS report, 2012
11
ART coverage, % 55 53–60
Expanded ART coverage, % 90 80–100 Assumption
Annual incidence of TB in PLHIV
  All 0.0395* 0.034–0.1 Shrestha, 200714
  TST-positive 0.047 0.034–0.1
  TST-negative 0.037 0.034–0.1
Relative risk of TB
  ART 0.33 0.27–0.39 Lawn 2011
15
  6-month IPT 0.89† 0.84–0.96 Akolo 201016
  36-month IPT (all) 0.51 0.27–0.93 Samandari, 2011
17
  36-month IPT in TST-positive 0.21 0.04–0.75
  TB infection control 0.87 0.63–1.00 Harries, 2002
12, 18
Sensitivity of screening and diagnostic test
  Cough 0.385 0.19–0.62 Getahun, 2011
13
  Four-symptom 0.789 0.58–0.91
  Sputum smear 0.36 0.09–0.50 Monkongdee, 2009
19
  Chest radiography 0.65 0.60–0.83 Cain, 2010
20




Specificity of screening and diagnostic test
  Cough 0.818 0.65–0.92 Getahun, 2011
13
  Four-symptom 0.496 0.29–0.70
  Sputum smear 0.99 0.98–1.00 Cain, 2010
20
  Chest radiography 0.85 0.35–1.00 Cain, 2010
20




Expected proportion of PLHIV testing
  TST-positive
  Active TB 0.65 0.50–0.74 Rangaka, 2007
23
  No active TB 0.26 0.19–0.35 Kerkhoff, 2012
24
*
Assuming 25% of HIV-positive people are TST-positive,
24
 we calculated the annual incidence of TB in PLHIV
†
Relative risk of TB from 6-month IPT is 0.67. Assuming 6-month IPT will only be effective in year 1, the average relative risk was calculated as 
0.89.
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TB = tuberculosis; HIV = human immunodeficiency virus; PLHIV = people living with HIV; ART=antiretroviral therapy; UNAIDS =Joint United 
Nations Programme on HIV/AIDS; TST = tuberculin skin test; IPT = isoniazid preventive therapy
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Table 3





USD Source (author, year, reference)
Diagnostic
  Sputum smear 1.60 2 tests 3.20 Vassall, 2011
25
  Chest radiography 7.80 1 test 7.80 Fairall, 2010
26
  Tuberculin skin test 6.20 1 test 6.20 2011 WHO ICF/IPT Guidelines
9
  Xpert 22.00 1 test 22.00 Vassall, 2011
25
Anti-tuberculosis treatment
  Drugs and DOT visits 437.20 DOTS course and DOTS visits 437.20 Dowdy, 2008
27
  TB hospitalisation 62 21 days average stay 1300.00 WHO-CHOICE
28
TB infection control
  Respirator 0.60 1 per nurse per week* 0.29 Data from a primary hospital, and
prices and building cost indices
from the Bureau of Economic
Research, Stellenbosch
University, Cape Town, South
Africa
  Surgical masks 0.17 1 per patient with cough per
visit†
2.50
  Windows: construction 3 years capital cost 0.35
  Windows: maintenance 3 years maintenance cost 0.12
  Fan Cost of capital and
maintenance for 3 years
0.13
INH
  6-month course 0.92 One course of 300 mg INH daily 16.40 International drug price indicator§
36-month course 3-year cost 103.50
  INH-related hepatitis†
LFT 4.50# 1 test Arnold, 201129
  Out-patient cost 3 LFT and 3 clinical visits 50 WHO-CHOICE
28
  In-patient cost 1 LFT and 7 days hospital stay 438
Antiretroviral therapy
  Antiretroviral drugs 274.50 3 years drug cost 867.20 Granich, 2012
30
  Monitoring visit (first) 34.30 1 visit 34.30
  Subsequent visits 25.70 2 visits (once every year) 55.50
*
Assuming 2 nurses per consulting room, the cost of respirators (life of 1 week) was calculated at US$2944 (in 2010 USD)
†
The cost calculation assumed annual out-patient visit/patient/year to be approximately 2.5
‡
We assumed that 10% of hepatitis cases were hospitalised for an average of 7 days after an LFT; all other cases were managed on an out-patient 





Using an exchange rate of US$1 = R8.8 and £1 = US$1.6.
USD = US dollars; WHO = World Health Organization; ICF = intensified case finding; IPT = INH preventive therapy; DOT = directly observed 
therapy; TB = tuberculosis; INH = isoniazid; LFT = liver function test; R = South African rand; £ = Great British pound.
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